DR. SUSAN J LITTLE, M.D.
Osteopathic Medicine at Washington St, San Diego, CA
License number
California G70574
Category
Osteopathic Medicine
Type
Internal Medicine
License number
California G70574
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
150 W Washington St SUITE 100, San Diego, CA 92103
Phone
(619) 543-8080
(619) 298-0177 (Fax)
(619) 298-0177 (Fax)
Professional information
Professor Of Medicine, University Of California San Diego
Position:
Professor of Medicine at University of California San Diego
Location:
Greater San Diego Area
Industry:
Medical Practice
Work:
University of California San Diego
since 1993
-
Professor of Medicine
Education:
Carleton College 1979 - 1983
Dr. Susan J Little, San Diego CA - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
150 W Washington St, San Diego 92103
UCSD Antiviral Research Center
220 Dickinson St STE A, San Diego 92103
(619) 543-8080 (Phone)
UCSD Antiviral Research Center
220 Dickinson St STE A, San Diego 92103
(619) 543-8080 (Phone)
Certifications:
Infectious Disease, 1994, Internal Medicine, 1991
Languages:
English
Education:
Medical School
Washington Center / School of Medicine
Graduated: 1987
Barnes-Jewish Hospital
U C S D Medical Center-Hillcrest
Washington Center / School of Medicine
Graduated: 1987
Barnes-Jewish Hospital
U C S D Medical Center-Hillcrest
Background:
Sanction: 1 time(s)
Susan Janet Little, San Diego CA
Specialties:
Internal Medicine, Infectious Disease
Work:
UC San Diego Health System
200 W Arbor Dr, San Diego, CA 92103 Va San Diego Healthcare System
3350 La Jolla Village Dr, San Diego, CA 92161
200 W Arbor Dr, San Diego, CA 92103 Va San Diego Healthcare System
3350 La Jolla Village Dr, San Diego, CA 92161
Education:
Washington University at St. Louis (1987)
Susan J Little, San Diego CA
Specialties:
Infectious Disease Specialist
Address:
200 W Arbor Dr, San Diego, CA 92103
150 W Washington St, San Diego, CA 92103
150 W Washington St, San Diego, CA 92103
Education:
Washington University, School of Medicine - Doctor of Medicine
UCSD Healthcare - Fellowship - Infectious Disease (Internal Medicine)
Barnes-Jewish Hospital - Residency - Internal Medicine
UCSD Healthcare - Fellowship - Infectious Disease (Internal Medicine)
Barnes-Jewish Hospital - Residency - Internal Medicine
Compositions And Methods For Evaluating Viral Receptor/Co-Receptor Usage And Inhibitors Of Virus Entry Using Recombinant Virus Assays
US Patent:
2005021, Sep 29, 2005
Filed:
Feb 14, 2003
Appl. No.:
10/504921
Inventors:
Douglas Richman - La Jolla CA, US
Mary Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos Petropoulos - Half Moon Bay CA, US
Neil Parkin - Belmont CA, US
Jeannette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
Mary Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos Petropoulos - Half Moon Bay CA, US
Neil Parkin - Belmont CA, US
Jeannette Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
International Classification:
C12Q001/70, C12N015/86
US Classification:
435005000, 435456000
Abstract:
The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic add of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
Method Of Evaluating A Patient Antibody Response To Envelope Proteins Of A Virus
US Patent:
7247439, Jul 24, 2007
Filed:
Feb 15, 2002
Appl. No.:
10/077027
Inventors:
Douglas Richman - La Jolla CA, US
Mary T. Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeannette M. Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
Mary T. Wrin - Fremont CA, US
Susan Little - San Diego CA, US
Christos J. Petropoulos - Half Moon Bay CA, US
Neil T. Parkin - Belmont CA, US
Jeannette M. Whitcomb - San Mateo CA, US
Wei Huang - Foster City CA, US
Assignee:
Monogram Biosciences, Inc. - South San Francisco CA
International Classification:
G01N 33/53
US Classification:
435 71, 435 5, 435 6, 435 721, 435 691, 4353201, 514 44, 536 2372
Abstract:
The invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.
Methods For Determining The Presence Of Antibodies Blocking Viral Infection
US Patent:
2011003, Feb 10, 2011
Filed:
Dec 10, 2009
Appl. No.:
12/635539
Inventors:
DOUGLAS RICHMAN - LA JOLLA CA, US
MARY T. WRIN - FREMONT CA, US
SUSAN LITTLE - SAN DIEGO CA, US
CHRISTOS J. PETROPOULOS - HALF MOON BAY CA, US
NEIL T. PARKIN - BELMONT CA, US
JEANNETTE WHITCOMB - SAN MATEO CA, US
WEI HUANG - FOSTER CITY CA, US
MARY T. WRIN - FREMONT CA, US
SUSAN LITTLE - SAN DIEGO CA, US
CHRISTOS J. PETROPOULOS - HALF MOON BAY CA, US
NEIL T. PARKIN - BELMONT CA, US
JEANNETTE WHITCOMB - SAN MATEO CA, US
WEI HUANG - FOSTER CITY CA, US
Assignee:
MONOGRAM BIOSCIENCES, INC. - SOUTH SAN FRANCISCO CA
International Classification:
C12Q 1/70
US Classification:
435 5
Abstract:
The present invention provides a method for identifying whether a compound inhibits entry of a virus into a cell which comprises: (a) obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus; (b) co-transfecting into a first cell (i) the nucleic acid of step (a), and (ii) a viral expression vector which lacks a nucleic acid encoding an envelope protein, and which comprises an indicator nucleic acid which produces a detectable signal, such that the first cell produces viral particles comprising the envelope protein encoded by the nucleic acid obtained from the patient; (c) contacting the viral particles produced in step (b) with a second cell in the presence of the compound, wherein the second cell expresses a cell surface receptor to which the virus binds; (d) measuring the amount of signal produced by the second cell in order to determine the infectivity of the viral particles; and (e) comparing the amount of signal measured in step (d) with the amount of signal produced in the absence of the compound, wherein a reduced amount of signal measured in the presence of the compound indicates that the compound inhibits entry of the virus into the second cell.